Evidence map›Paper›PMID 40828344›Full record

ReviewCurrent neurology and neuroscience reports2025

Pharmacological Strategies for the Treatment of Restless Legs Syndrome.

David Anguizola, Alba Garcia Aragón, Alejandro Lopez Jimenez, Valentin Sainz, Diego Garcia-Borreguero

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The evolving treatment landscape of restless legs syndrome.Therapeutic advances in neurological disorders · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David AnguizolaInstituto Europeo del Sueño, Panama City, Panamá.
Alba Garcia AragónSleep Research Institute, Madrid, Spain.
Alejandro Lopez JimenezInstituto Europeo del Sueño, Panama City, Panamá.
Valentin SainzSleep Research Institute, Madrid, Spain.
Diego Garcia-BorregueroSleep Research Institute, Madrid, Spain. dgb@iis.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewRestless legs syndrome (RLS) significantly impacts patients’ quality of life and requires effective management strategies. While dopaminergic agonists have been widely used in the past, concerns about symptom augmentation highlight the need for alternative therapies. RECENT

findingsNon-dopaminergic agents, such as α2δ ligands and iron supplementation, are viable alternatives with favorable safety profiles. A comprehensive approach that includes non-pharmacological measures, individualized treatment plans, and regular monitoring for iron deficiency is essential for optimal symptom management. We present a treatment plan using iron replacement and long-term use of non-dopaminergic agents. Dopamine agonists are reserved for specific, time-limited situations only, while opioids should be kept for treatment-resistant cases. As research advances, future RLS management will likely be individualized, further enhancing therapeutic outcomes and ultimately improving patients’ overall quality of life.

Indexed as

Dopamine AgonistsRestless Legs SyndromeHumansIronQuality of LifeDopamine AgonistsIronDopamine agonistsDopaminergic augmentation of symptomsIron supplementationPharmacological managementRestless legs syndromeα2δ ligands

Identifiers

PMID40828344

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.